Key Performance
More- Earnings Score: 86
- Momentum Score: 34
- True Yield: N/A
- Financial Health Score: 62
%20scale(1,1)}%2025%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(1,1)}}%20%23ewMkZ6d8Hun3_ts%20{animation:%20ewMkZ6d8Hun3_ts__ts%204000ms%20linear%20infinite%20normal%20forwards}@keyframes%20ewMkZ6d8Hun3_ts__ts%20{%200%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}%2025%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}}%20]]%3e%3c/style%3e%3cdefs%3e%3clinearGradient%20id='ewMkZ6d8Hun2-fill'%20x1='12.5'%20y1='23.5001'%20x2='-0.868518'%20y2='16.4047'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun2-fill-0'%20offset='0%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun2-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3clinearGradient%20id='ewMkZ6d8Hun3-fill'%20x1='31.5059'%20y1='27.1026'%20x2='10.2884'%20y2='14.9373'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun3-fill-0'%20offset='4.7%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun3-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3c/defs%3e%3cg%20id='ewMkZ6d8Hun2_ts'%20transform='translate(24.943161,19.954806)%20scale(1,1)'%3e%3cpath%20d='M14.8466,29.2814c0,0-14.408088-4.6983-12.05895-19.79995c0,0,1.50345,4.85085,4.13448,5.30845s-2.03592,4.6373,7.92447,14.4915Z'%20transform='translate(-24.943161,-19.954806)'%20fill='url(%23ewMkZ6d8Hun2-fill)'/%3e%3c/g%3e%3cg%20id='ewMkZ6d8Hun3_ts'%20transform='translate(24.9787,20.012362)%20scale(1,1)'%3e%3cpath%20d='M37.4922,21.9282l4.0719.244v-12.81353C31.0713,3.28748,17.7595,7.6502,17.7595,7.6502c.3445-4.51526-3.5707-5.52204-3.5707-5.52204c2.5371,1.52542.3132,6.22373.3132,6.22373C13.0299,0.084092,0,1.02986,0,1.02986C8.92672,4.35528,6.70287,7.98579,6.8908,16.6197c.18794,8.6034,8.3943,12.9966,8.3943,12.9966l-6.60895-.2441v13.2407c0,0,5.48135,2.3797,13.68765,3.1729v-22.3017h-4.4477c-1.0023,0-1.942-.8237-1.942-1.8v-5.7356c0-.9763.9397-1.8,1.942-1.8h4.4477v-1.3424h5.0115v1.3424h5.0115c1.0023,0,1.848.7932,1.848,1.8v5.7356c0,.9763-.8144,1.8-1.848,1.8h-5.0115v22.5153h.2819c11.1192-.0611,15.9428-7.3221,16.256-13.3017.4698-7.7492-6.421-10.7695-6.421-10.7695Z'%20transform='translate(-24.9787,-20.012361)'%20fill='url(%23ewMkZ6d8Hun3-fill)'/%3e%3c/g%3e%3c/svg%3e)
Latest Research & News
Hims & Hers Health faces a securities fraud class action lawsuit after the FTC alleged the telehealth provider shared consumers' sensitive health information with third-party advertising platforms while claiming privacy protection, and deceived users about billing and cancellation practices. The stock declined 14.73% on July 29, 2026, following the FTC announcement. Investors who purchased securities between August 4, 2025 and July 29, 2026 can file lead plaintiff applications by November 2, 2026.
09/15/2026, 10:36 PM • GlobeNewswire
A securities fraud class action lawsuit has been filed against Hims & Hers Health, Inc. (HIMS) for allegedly making materially false statements about its privacy practices. The FTC accused HIMS of sharing customers' medical information with third-party advertisers including Meta and Snap. Following the FTC lawsuit announcement on July 29, 2026, HIMS stock declined 14.73%. Investors who purchased HIMS securities between August 4, 2025 and July 29, 2026 can seek lead plaintiff status by November 2, 2026.
09/15/2026, 3:38 PM • GlobeNewswire
A class action lawsuit has been filed against Hims & Hers Health, Inc. for allegedly making false statements and failing to disclose that it shares consumers' health information with third-party advertising platforms and charges for prescriptions immediately after intake forms are submitted. The FTC, California, and Utah filed a separate lawsuit on July 29, 2026, alleging deceptive practices including difficult subscription cancellations and misleading privacy claims. The stock fell 14.73% following the FTC action.
09/14/2026, 8:14 PM • GlobeNewswire
Kaplan Fox has filed securities class action lawsuits against three companies: Cogent Communications for allegedly misrepresenting demand and backlog for optical wavelengths (Class Period: Feb 29, 2024 - May 1, 2026), Hims & Hers Health (Class Period: Aug 4, 2025 - July 29, 2026), and EquipmentShare.Com related to its January 2026 IPO. Investors have until September 21, 2026 to seek lead plaintiff status in the Cogent and EquipmentShare cases, and November 2, 2026 for Hims & Hers.
09/14/2026, 11:00 AM • GlobeNewswire
A securities class action has been filed against Hims & Hers Health, Inc. following FTC allegations that the company failed to disclose immediate prescription charges, made it difficult for consumers to cancel subscriptions, and shared health information with third-party advertising platforms without proper consent. The stock fell 14.73% on July 29, 2026, following the FTC lawsuit announcement.
09/14/2026, 11:00 AM • GlobeNewswire
A class action lawsuit has been filed against Hims & Hers Health, Inc. alleging the telehealth company made false statements about consumer privacy and billing practices. The FTC filed a lawsuit on July 29, 2026, claiming Hims & Hers shared sensitive health information with third-party advertising platforms like Meta and Snap, and charged consumers for prescriptions immediately after intake forms despite promising consultation with medical providers. The stock declined nearly 15% following the FTC announcement. Investors with substantial losses can seek lead plaintiff status before November 2, 2026.
09/13/2026, 4:40 PM • GlobeNewswire
The FTC filed a lawsuit against Hims & Hers Health, Inc. on July 29, 2026, alleging the telehealth provider shared consumers' sensitive health information with third-party advertising platforms while claiming to maintain privacy, and deceived users about billing and cancellation practices. The stock declined 14.73% on the news. A class action lawsuit has been filed for investors who purchased HIMS securities between August 4, 2025 and July 29, 2026, with a November 2, 2026 deadline to file a lead plaintiff motion.
09/09/2026, 2:45 PM • GlobeNewswire
Kaplan Fox & Kilsheimer LLP has filed class action lawsuits against Wix.com, Hertz Global Holdings, and Hims & Hers Health on behalf of investors who suffered losses. The Wix lawsuit covers investors from February 19, 2025 to May 12, 2026, alleging the company misrepresented its AI capabilities while costs accelerated. Wix's stock fell 27.1% following disappointing Q1 2026 results. Investors with losses are encouraged to contact the firm before respective deadlines.
09/08/2026, 12:58 PM • GlobeNewswire
A class action lawsuit has been filed against Hims & Hers Health, Inc. alleging securities fraud. The complaint claims the company made false statements about sharing consumer health information with third-party advertisers, charging for prescriptions immediately despite promising consultations, and failing to disclose regulatory scrutiny and potential penalties. Investors who purchased Hims securities between August 4, 2025 and July 29, 2026 may be eligible to join the case.
09/07/2026, 12:00 PM • GlobeNewswire
Rosen Law Firm has filed a class action lawsuit on behalf of Hims & Hers Health, Inc. investors for the period between August 4, 2025 and July 29, 2026. The lawsuit alleges that Hims made materially false and misleading statements regarding consumer health data sharing with third-party advertisers, premature prescription charges despite promised consultations, and undisclosed regulatory scrutiny and potential penalties. Investors who purchased securities during the class period may be eligible for compensation.
09/04/2026, 3:38 PM • GlobeNewswire
Kaplan Fox has filed class action lawsuits against three companies: Hims & Hers for allegedly failing to disclose immediate prescription charges, sharing health data with third parties, and making subscription cancellations difficult; Hyliion Holdings for undisclosed issues during May-June 2026; and Innventure for regulatory concerns from November 2025 to August 2026. Investors with losses are encouraged to contact the firm before respective deadlines.
09/04/2026, 1:45 PM • GlobeNewswire
A securities fraud class action lawsuit has been filed against Hims & Hers Health, Inc. (HIMS) for allegedly making material misstatements about its privacy practices. The FTC accused HIMS of sharing customers' medical information with third-party advertisers including Meta and Snap, and charging consumers for prescriptions immediately despite promising consultation with medical providers. The stock declined 14.73% on the news. Investors who purchased HIMS securities between August 4, 2025 and July 29, 2026 can seek lead plaintiff status by November 2, 2026.
09/04/2026, 1:41 PM • GlobeNewswire
A securities fraud class action lawsuit has been filed against Hims & Hers Health, Inc. following an FTC lawsuit alleging the telehealth provider shared consumers' sensitive health information with third-party advertising platforms and engaged in deceptive billing practices. The stock declined 14.73% on the news. Investors who purchased HIMS securities between August 4, 2025 and July 29, 2026 have until November 2, 2026 to file a lead plaintiff motion.
09/03/2026, 9:00 AM • GlobeNewswire
Hims & Hers Health (NYSE: HIMS) faces a securities class action lawsuit following an FTC complaint alleging the company engaged in deceptive health data sharing with advertising platforms like Meta and Snap, and violated billing regulations by charging consumers for prescriptions before medical consultations. The lawsuit, filed by the FTC alongside Utah and Los Angeles County, also accuses Hims of using dark patterns to prevent subscription cancellations. The stock dropped 14.7% ($4.32) on July 29, 2026, erasing over $970 million in market value.
09/02/2026, 5:34 PM • GlobeNewswire
A securities class action lawsuit has been filed against Hims & Hers Health, Inc. for the period between August 4, 2025 and July 29, 2026. The FTC sued the company for failing to disclose immediate prescription charges, making subscription cancellations difficult, and sharing consumer health information with third-party advertising platforms like Meta and Snap. The stock fell 14.73% following the FTC allegations. The lead plaintiff deadline is November 2, 2026.
09/02/2026, 1:43 PM • GlobeNewswire
Peers
Statistics
MoreInformation as of 09/15/2026
Company Profile
Hims & Hers Health, Inc. operates as a consumer-first health and wellness platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, Canada, Germany, the Republic of Ireland, France, Spain, Australia, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides personalized health and wellness products; over-the-counter drug and device products, cosmetics, and supplement products primarily focusing on general wellness, skincare, sexual health and wellness, and hair care under the Hims & Hers brand name; and laboratory testing services to measure a set of biomarkers. Additionally, it offers medical consultation, post-consultation support services, and delivery of laboratory testing results services. Further, the company provides treatments and products for various chronic conditions related to hormone health, weight loss, dermatology, and mental health. The company offers its products through retail partnerships, in stores, and online. The company was formerly known as Hims, Inc. and changed its name to Hims & Hers Health, Inc. in January 2021. The company was founded in 2017 and is based in San Francisco, California.